If you have been reading about intranasal delivery and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-26. Numbers and descriptions here follow the published literature rather than marketing material.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
| Property | Value | Notes |
|---|---|---|
| Primary research models | Rodent studies | Largest share of published data |
| Reported markers | BDNF and NGF expression | Measured mainly in animal tissue |
| Common administration | Intranasal | Matches the registered formulation |
| Blood residence time | Minutes | Rapid enzymatic degradation |
| Evidence quality | Small trials, limited replication | Noted repeatedly in reviews |
Verification of a supplied batch generally combines a certificate of analysis with independent testing, because certificates are self-reported documents. A typical package includes a chromatographic trace, a mass spectrum, and a stated water or counter-ion content. Batch-to-batch consistency matters more than a single purity figure when results are compared across experiments. No single mandatory standard governs research-grade peptide release, so laboratories are expected to define their own acceptance criteria. Residual trifluoroacetate from purification is a frequently overlooked counter-ion.
Lyophilized material is chemically stable for extended periods when kept dry, cold, and protected from light. The powder is hygroscopic, so vials should be warmed to room temperature before opening to reduce condensation on the contents. Once dissolved, the peptide is far less stable because peptide bonds are susceptible to hydrolysis and the methionine residue can oxidize. Solutions are typically aliquoted and held at 2-8 °C for short intervals or frozen for longer ones, and repeated freeze-thaw cycles should be avoided.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Published research has focused mainly on neurological and cognitive endpoints in animal models, with proposed mechanisms involving brain-derived neurotrophic factor and related signalling pathways. A substantial share of the human data originates from a limited number of research groups, and independent replication in other countries remains sparse. Regulatory status reflects that distribution: the peptide is registered as a medicine in Russia and appears in some neighbouring markets, while elsewhere it is handled as a research chemical without approved therapeutic labelling. Questions about dose-response relationships, long-term effects, and comparability across studies are still open.
Lyophilised powder is normally kept at -20 °C in a desiccated container, with some suppliers recommending -80 °C for long-term archival storage. Repeated freeze-thaw cycles are the most common cause of avoidable loss, so aliquoting before freezing reduces variability between working sessions. Dissolved peptide is far less stable than the dry solid and is usually prepared fresh or held briefly at 4 °C. Aqueous solutions support both hydrolysis of the backbone and oxidation of the N-terminal methionine, and these two routes dominate degradation under ordinary laboratory conditions.
Identity and purity are confirmed with reversed-phase high-performance liquid chromatography, typically monitored at 214 nanometres where the peptide bond absorbs. Mass spectrometry, either electrospray or MALDI-TOF, verifies molecular mass against the theoretical value and detects truncation or adduct formation. Amino acid analysis and peptide mapping provide additional confirmation when required. The most frequently reported impurities are deletion sequences from incomplete coupling, methionine sulfoxide from oxidation, and dimeric species formed through non-covalent aggregation. Impurity profiles depend strongly on the synthesis and purification route chosen by the producer.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
== Nuclear fuel == Uranium-233 has been used as fuel in several reactor types and has been proposed for use in new designs. Uranium-233 can be bred in either fast reactors or thermal reactors, unlike the uranium-238-based fuel cycles which require the superior neutron economy of a fast reactor in order to breed plutonium, that is, to produce more fissile material than is consumed. In 1968, the Molten-Salt Reactor Experiment at Oak Ridge became the first reactor to operate on uranium-233. The long-term strategy of the nuclear power program of India, which has substantial thorium reserves, is to move to a nuclear program breeding uranium-233 from thorium feedstock.
Insulin is usually given subcutaneously, either by injections or by an insulin pump. In acute care settings, insulin may also be given intravenously. Insulins are typically characterized by the rate at which they are metabolized by the body, yielding different peak times and durations of action. Faster-acting insulins peak quickly and are subsequently metabolized, while longer-acting insulins tend to have extended peak times and remain active in the body for more significant periods. Examples of rapid-acting insulins (peak at ~1 hour) are:
=== Cuisine === Ghanaian cuisine includes an assortment of soups and stews with varied seafoods; most Ghanaian soups are prepared with vegetables, meat, poultry or fish. Fish is in the diet with tilapia, roasted and fried whitebait, smoked fish and crayfish, all being components of Ghanaian dishes. Banku (akple) is a starchy food made from ground corn (maize), and cornmeal based staples kɔmi (kenkey) and banku (akple) may be accompanied by some form of fried fish (chinam) or grilled tilapia and a spicy condiment made from raw red and green chillies, onions and tomatoes (pepper sauce). Banku and tilapia is a combo served in some restaurants. Fufu is the most common exported Ghanaian dish and is a delicacy across the African diaspora. Rice is an established staple meal across the country, with various rice-based dishes serving as breakfast, lunch and dinner, the main variants are waakye, plain rice and stew (either kontomire or tomato gravy), fried rice and jollof rice.
== Validation or verification == The main difference between the two is that validation is focused on ensuring that the device meets the needs and requirements of its intended users and the intended use environment, whereas verification is focused on ensuring that the device meets its specified design requirements. For instance, a regulatory agency (such as CE or FDA) may ensure that a product has been validated for general use before approval. An individual laboratory that introduces such an approved medical device may then not need to perform their own validation, but generally still need to perform verification to ensure that the device works correctly.
== Production of a peptide microarray == A peptide microarray is a planar slide with peptides spotted onto it or assembled directly on the surface by in-situ synthesis. Whereas peptides spotted can undergo quality controls that include mass spectrometer analysis and concentration normalization before spotting and result from a single synthetic batch, peptides synthesized directly on the surface may suffer from batch-to-batch variation and limited quality control options. However, peptide synthesis on chip allows the parallel synthesis of tens of thousands of peptides providing larger peptide libraries paired with lower synthesis costs. Peptides are ideally covalently linked through a chemoselective bond leading to peptides with the same orientation for interaction profiling. Some alternative procedures describe unspecific covalent binding and adhesive immobilization. However, lithographic methods can be used to overcome the problem of excessive number of coupling cycles. Combinatorial synthesis of peptide arrays onto a microchip by laser printing has been described, where a modified colour laser printer is used in combination with conventional solid-phase peptide synthesis chemistry. Amino acids are immobilized within toner particles, and the peptides are printed onto the chip surface in consecutive, combinatorial layers. Melting of the toner upon the start of the coupling reaction ensures that delivery of the amino acids and the coupling reaction can be performed independently.
Sources: en.wikipedia.org
Opium was prohibited in many countries during the early 20th century, leading to the modern pattern of opium production as a precursor for illegal recreational drugs or tightly regulated, highly taxed, legal prescription drugs. In 1980, 2,000 tons of opium supplied all legal and illegal uses. Worldwide production in 2006 was 6610 tonnes—about one-fifth the level of production in 1906; since then, opium production has fallen. In 2002, the price for one kilogram of opium was US$300 for the farmer, US$800 for purchasers in Afghanistan, and US$16,000 on the streets of Europe before conversion into heroin. Opium production increased considerably, surpassing 5,000 tons in 2002 and reaching 8,600 tons in Afghanistan and 840 tons in the Golden Triangle in 2014. The World Health Organization has estimated that current production of opium would need to increase fivefold to account for total global medical need. Solar energy panels in use in Afghanistan have allowed farmers to dig their wells deeper, leading to a bumper crop of opium year after year. In a 2023 report, poppy cultivation in southern Afghanistan was reduced by over 80% as a result of Taliban campaigns to stop its use toward opium. This included a 99% reduction of opium growth in the Helmand Province. In November 2023, a U.N report showed that in the entirety of Afghanistan, poppy cultivation dropped by over 95%, removing it from its place as being the world's largest opium producer.
MPs' basic salary is set to rise by 2.8% to £93,904 from April. Darren Millar tells the Senedd he was in the "right place at the right time" as he defends his decision to attend the National Prayer Breakfast in the United States and miss a vote on the Welsh Government's budget. Millar also says he was promoting Welsh interests while in the US. Simon Case, the former Cabinet Secretary, is appointed as the chair of the Team Barrow Delivery Board, a board that will oversee a £200m project to redevelop Barrow-in-Furness, Cumbria. 11 February – Labour suspends 11 councillors in Greater Manchester as part of its investigation into a WhatsApp group in which offensive messages were exchanged. James Garnor resigns as a member of Whittlebury Parish Council after a video was share that appeared to show an explosive device being triggered by a cat. 12 February – A review into the events leading up to the murder of David Amess finds that his killer, Ali Harbi Ali, was exited from the government's Prevent anti-terror programme "too quickly" and that its handling of him was "sub-optimal". 13 February – A BBC News investigation discovers Chancellor Rachel Reeves was the subject of an expenses investigation while she was a senior manager at Halifax Bank of Scotland in the late 2000s. Her online CV is also reported to have exaggerated the length of time she was employed by the Bank of England. In response, Reeves says that no concerns were raised with her at the time of the investigation.
The right to freedom of speech and association is guaranteed by Article 14(1) of the Constitution of Singapore, although there are provisions in the subsequent subsection that regulate them. The government has restricted freedom of speech and freedom of the press as well as some civil and political rights. In 2023, Singapore was ranked 129th out of 180 nations by Reporters Without Borders on the global Press Freedom Index. Freedom House ranks Singapore as "partly free" in its Freedom in the World report, and the Economist Intelligence Unit ranks Singapore as a "flawed democracy", the second freest rank of four, in its "Democracy Index". All public gatherings of five or more people require police permits, and protests may legally be held only at the Speakers' Corner. In the Corruption Perceptions Index, which ranks countries by "perceived levels of public sector corruption", Singapore has consistently ranked as one of the least corrupt countries in the world, in spite of being illiberal. Singapore's unique combination of a strong, soft-authoritarian government with an emphasis on meritocracy is known as the "Singapore model", and is regarded as a key factor behind Singapore's political stability, economic growth, and harmonious social order. In 2021, the World Justice Project's Rule of Law Index ranked Singapore as 17th overall among the world's 193 countries for adherence to the rule of law.
In February 2018, The Marshall Project published an investigation reporting that the new label allowed Johnson & Johnson to market Invega Sustenna as a way to keep people out of prison or jail. John Snook, executive director of the Treatment Advocacy Center, described the "stay-out-of-jail" marketing approach as a "depressing commentary" on the state of mental health treatment. Critics noted that the PRIDE study did not compare Invega Sustenna with other long-acting injectable antipsychotics, only with daily oral antipsychotics, and that the reduced rate of incarceration was likely due to improved drug adherence rather than a unique property of paliperidone palmitate. A 2022 review of internal pharmaceutical industry documents, published in the Journal of Correctional Health Care, identified Janssen as one of at least two companies that directly marketed antipsychotics to jails and prisons to increase sales. The review found that marketing strategies included targeted promotions, indirect "educational" advertising, and efforts to influence state formulary advisory boards. Concerns have also been raised about industry influence on the evidence base for long‑acting injectable (LAI) antipsychotics. In a 2024 paper in Accountability in Research, Lisa Cosgrove and colleagues presented a case analysis arguing that systematic reviews comparing LAIs to oral antipsychotics can be "shaped by commercial interests" and that financial conflicts of interest among review authors may "undermine patient‑centered models of recovery and care."
=== Celebrex intellectual property settlement (2012) === Brigham Young University (BYU) said a professor of chemistry, Dr. Daniel L. Simmons, discovered an enzyme in the 1990s that led towards development of Celebrex. BYU was originally seeking a 15% royalty on sales, equating to $9.7 billion. A research agreement had been made between BYU and Monsanto, whose pharmaceutical business was later acquired by Pfizer, to develop a better aspirin. The enzyme Dr. Simmons claims to have discovered would induce pain and inflammation while causing gastrointestinal problems and Celebrex is used to reduce those issues. A six-year battle ensued because BYU claimed that Pfizer did not give Dr. Simmons credit or compensation, while Pfizer claimed that it had met all obligations regarding the Monsanto agreement. In May 2012, Pfizer settled the allegations, agreeing to pay $450 million.
Sources: en.wikipedia.org
The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.
The compound is registered as a medicine in Russia, so clinical work has concentrated there. Trials elsewhere are few and generally small. This geographic concentration is a recognized limitation in evidence reviews.
Some fraction may reach the central nervous system through olfactory pathways, and this is often cited as the rationale for the nasal route. The size of that fraction in humans is not well quantified. Blood concentrations after nasal dosing are low, which complicates measurement.
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.